title: Immunotoxins for ex vivo marrow purging in autologous bone marrow transplantation for acute nonlymphocytic leukemia.
abstract: Two potent antimyeloid immunotoxins (IT) were generated by conjugating AML-2-23 (anti-CD14) and MCS-2 (anti-CD13) monoclonal antibodies (mAb) to the ribosome-inactivating phytotoxin, ricin. Both IT selectively bound to target cells, inhibited protein synthesis, and prevented the clonogenic growth of fresh marrow blasts from acute nonlymphocytic leukemia patients as well as KG-1 (ANLL) cells. Cryopreservation did not inhibit IT activity. We conclude that AML-2-23-ricin and MCS-2-ricin show potential for effective ex vivo marrow purging in autologous bone marrow transplantation (ABMT) for ANLL. To our knowledge, this study represents the first evidence of the clinical potential of IT in high-risk ANLL.
authors: Department of Therapeutic Radiology, University of Minnesota, Minneapolis 55455.
authors: D E
authors: DE
authors: Myers
authors: F M
authors: FM
authors: Uckun
authors: E D
authors: ED
authors: Ball
authors: D A
authors: DA
authors: Vallera
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000943:Antigens, Differentiation / Q000276:immunology*; D016026:Bone Marrow Transplantation; D018826:CD13 Antigens; D005434:Flow Cytometry; D005615:Freezing; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D018950:Lipopolysaccharide Receptors; D014176:Protein Biosynthesis; D012276:Ricin; D014021:Tissue Preservation
chemical_list: D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D018950:Lipopolysaccharide Receptors; D012276:Ricin; D018826:CD13 Antigens